*Result*: Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France.
Rossi BV, Abusief M, Missmer SA. Modifiable risk factors and infertility. Am J Lifestyle Med. 2016;10:220–31. https://doi.org/10.1177/1559827614558020 . (PMID: 10.1177/1559827614558020)
NHS. Infertility 2017. https://www.nhs.uk/conditions/infertility/ . Accessed 9 Apr 2021.
Santé Publique France. La fertilité des couples en France. Numéro thématique. Enjeux environnementaux pour la fertilité humaine n.d. /notices/la-fertilite-des-couples-en-france.-numero-thematique.-enjeux-environnementaux-pour-la-fertilite-humaine (accessed May 3, 2021).
Rochebrochard ÉdeL. 1 enfant sur 30 conçu par assistance médicale à la procréation en France. Popul Soc. 2018;556:1–4.
Inserm. Infertilité. Des difficultés à concevoir d’origines multiples. Inserm - Sci Pour Santé n.d. https://www.inserm.fr/information-en-sante/dossiers-information/infertilite . Accessed 28 Jan 2021.
Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–40. https://doi.org/10.1097/00006254-198906000-00004 . (PMID: 10.1097/00006254-198906000-000042660037)
European Medicines Agency (EMA). Summary of product characteristics 2023. European public assessment reports (EPAR). REKOVELLE, INN-follitropin delta. n.d.
European Medicines Agency (EMA). Summary of product characteristics 2024. European public assessment reports (EPAR). GONAL-f, INN-follitropin alfa. n.d.
European Medicines Agency (EMA). Summary of product characteristics 2023. European public assessment reports (EPAR). Puregon, INN-follitropin beta. n.d.
Palomba S, Caserta D, Levi-Setti PE, Busnelli A. Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis. J Ovarian Res. 2024;17:60. https://doi.org/10.1186/s13048-024-01372-w . (PMID: 10.1186/s13048-024-01372-w3848627610938807)
Doroftei B, Ilie O-D, Anton N, Marcu O-A, Scripcariu I-S, Ilea C. A narrative review discussing the efficiency of personalized dosing algorithm of follitropin delta for ovarian stimulation and the reproductive and clinical outcomes. Diagnostics. 2023;13:177. https://doi.org/10.3390/diagnostics13020177 . (PMID: 10.3390/diagnostics13020177366729879858569)
Nyboe Andersen A, Nelson SM, Fauser BCJM, García-Velasco JA, Klein BM, Arce J-C, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107:387-396.e4. https://doi.org/10.1016/j.fertnstert.2016.10.033 . (PMID: 10.1016/j.fertnstert.2016.10.03327912901)
Qiao J, Zhang Y, Liang X, Ho T, Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod Oxf Engl. 2021;36:2452–62. https://doi.org/10.1093/humrep/deab155 . (PMID: 10.1093/humrep/deab155)
Ishihara O, Nelson SM, Arce J-C. Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients. Reprod Biomed Online. 2022;44:177–84. https://doi.org/10.1016/j.rbmo.2021.09.014 . (PMID: 10.1016/j.rbmo.2021.09.01434799275)
Nelson SM, Shaw M, Alrashid K, Anderson RA. Individualized dosing of follitropin delta affects live birth and safety in in vitro fertilization treatment: an individual participant data meta-analysis of randomized controlled trials. Fertil Steril. 2024;122:445–54. https://doi.org/10.1016/j.fertnstert.2024.05.143 . (PMID: 10.1016/j.fertnstert.2024.05.14338750874)
Xue W, Lloyd A, Falla E, Roeder C, Papsch R, Bühler K. A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. Int J Womens Health. 2019;11:319–31. https://doi.org/10.2147/IJWH.S193048 . (PMID: 10.2147/IJWH.S193048311910406524790)
Sivignon M, Palencia R, Roze S. Cost minimisation analysis of follitropin delta versus follitropin alfa in assisted reproductive technologies (IVF/ICSI) in the United Kingdom. Value Health. 2016;19:A403. https://doi.org/10.1016/j.jval.2016.09.326 . (PMID: 10.1016/j.jval.2016.09.326)
Grynberg M, Murphy C, Doré C, Fresneau L, Paillet S, Petrica N, et al. A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. J Med Econ. 2019;22:108–15. https://doi.org/10.1080/13696998.2018.1551226 . (PMID: 10.1080/13696998.2018.1551226)
ISPOR. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation. ISPOR Int Soc Pharmacoeconomics Outcomes Res n.d. https://www.ispor.org/heor-resources/good-practices/article/principles-of-good-practice-for-decision-analytic-modeling-in-health-care-evaluation . Accessed 5 Feb 2026.
Haute Autorité de Santé. Choix méthodologiques pour l’évaluation économique à la HAS. Haute Aut Santé n.d. https://www.has-sante.fr/jcms/r_1499251/fr/choix-methodologiques-pour-l-evaluation-economique-a-la-has . Accessed 3 Jan 2023.
Suivi et orientation des femmes enceintes en fonction des situations à risque identifiées. Rev Sage-Femme. 2007;6:216–8. https://doi.org/10.1016/S1637-4088(07)79647-5 .
National Collaborating Centre for Women’s and Children’s Health (Great Britain), National Institute for Health and Clinical Excellence (Great Britain). Antenatal care: routine care for the healthy pregnant woman. London: RCOG Press; 2008.
National Collaborating Centre for Women’s and Children’s Health (Great Britain) et National Institute for Health and Clinical Excellence (Great Britain) - 2008 - Antenatal care routine care for the healthy pregn.pdf n.d.
Fertility problems: assessment and treatment 2017:51.
The Management of Ovarian Hyperstimulation Syndrome - Royal College of Obstetricians & Gynaecologists, Green-top Guideline No.5, February 2016.pdf n.d.
French National Health Insurance tariffs n.d. https://www.ameli.fr/assure . Accessed 6 Nov 2024.
ATIH. ATIH : Agence technique de l’information sur l’hospitalisation n.d. https://www.atih.sante.fr/ . Accessed 30 Oct 2024.
INSEE. Indice des prix à la consommation - Base 2015 - Ensemble des ménages - France - Services de santé n.d. https://www.insee.fr/fr/statistiques/serie/001763845 . Accessed 3 Jan 2023.
Barriere P, Porcu-Buisson G, Hamamah S. Cost-effectiveness analysis of the gonadotropin treatments HP-hMG and rFSH for assisted reproductive technology in France: a Markov model analysis. Appl Health Econ Health Policy. 2018;16:65–77. https://doi.org/10.1007/s40258-017-0361-7 . (PMID: 10.1007/s40258-017-0361-729124676)
Han S, Yang R, Guan X, Carette J, Markert M, Liu C, et al. P-729 Cost-effectiveness of follitropin delta versus follitropin alfa for controlled ovarian stimulation for IVF/ICSI in China. Hum Reprod. 2025;40:deaf097.1034. https://doi.org/10.1093/humrep/deaf097.1034 . (PMID: 10.1093/humrep/deaf097.1034)
Porcu-Buisson G, Maignien C, Swierkowski-Blanchard N, Rongières C, Ranisavljevic N, Oger P, et al. Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF/ICSI procedures (DELTA Study). Eur J Obstet Gynecol Reprod Biol. 2024;293:21–6. https://doi.org/10.1016/j.ejogrb.2023.12.011 . (PMID: 10.1016/j.ejogrb.2023.12.01138100937)
Skedgel C, Cubi-Molla P, Mott D, Gameiro S, Boivin J, Al-Janabi H, et al. Unmet parenthood goals, health-related quality of life and apparent irrationality: understanding the value of treatments for infertility. Pharmacoecon Open. 2023;7:337–44. https://doi.org/10.1007/s41669-023-00402-5 . (PMID: 10.1007/s41669-023-00402-53692071910016171)
Connolly M, Gallo F, Hoorens S, Ledger W. Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK. Hum Reprod Oxf Engl. 2009;24:626–32. https://doi.org/10.1093/humrep/den435 . (PMID: 10.1093/humrep/den435)
Ágh T, Gáspár K, Nagy B, Lehmann M, Kaló Z. The value of a child born in the European Union 2018. https://doi.org/10.1556/032.2018.68.2.6 .
The European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE), Smeenk J, Wyns C, De Geyter C, Kupka M, Bergh C, et al. ART in Europe, 2019: results generated from European registries by ESHRE†. Hum Reprod 2023;38:2321–38. https://doi.org/10.1093/humrep/dead197 .
*Further Information*
*Background: Follitropin delta, using a personalized dosing regimen, is an effective treatment option for women undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).
Objective: The aim of this study was to develop a model to determine cost effectiveness of follitropin delta compared with follitropins alfa and beta for women undergoing IVF/ICSI in France.
Methods: A decision-tree model was developed comparing the outcomes of treatment with follitropin delta versus other follitropins through ongoing pregnancy (OP) and live birth (LB) rates in fresh cycles. Pooled data from the pivotal clinical trials ESTHER (EU + rest of world; NCT01956110), GRAPE (Pan-Asia; NCT03296527), and STORK (Japan; NCT03228680) was used for the economic model. The analyses were stratified by age and ovarian reserve profile and reflected a single COS cycle. Costs were estimated from the healthcare perspective in France, and uncertainty was assessed through sensitivity analyses.
Results: In women with an elevated anti-Müllerian hormone level (≥15 pmol/L), follitropin delta achieved a higher rate of LB (31.4% vs 25.8%, p = 0.01) and a numerically higher rate of OP (35.7% vs 31.6%) compared with follitropins alfa/beta. Additionally, treatment with follitropin delta was associated with numerically fewer miscarriages (4.3% vs 5.8%) and lower ovarian hyperstimulation syndrome (OHSS) incidence (8.2% vs 11.5%). Total treatment cycle cost with/without delivery cost was €5479/€4099 for follitropin delta, €5335/€4191 for follitropin alfa, and €5387/€4243 for follitropin beta. The incremental cost-effectiveness ratio was €2579/LB for follitropin delta versus follitropin alfa. Follitropin beta was shown to be less efficient, and more costly (i.e. dominated). Excluding the delivery cost, follitropin delta was more efficient and less costly (i.e. dominant) versus other follitropins. Probabilistic sensitivity analyses supported the deterministic results, showing > 76% probability of follitropin delta being dominant when assessing cost per additional OP. Similar results were observed in the overall population of women.
Conclusions: Follitropin delta provides an effective alternative to follitropin alfa and beta with a potential cost-savings opportunity, excluding the delivery cost, due to higher OP and LB rates in the fresh cycle transfers.
(© 2026. The Author(s).)*
*Declarations. Funding: This study has been funded by Ferring Pharmaceuticals which is developing follitropin delta. The study sponsor participated in the study design, data collection, analysis and interpretation of data, writing of the manuscript, and in the decision to submit the article for publication. Competing interests: Professor Samir Hamamah has received consultancy fees from Ferring Pharmaceuticals and Gedeon Richter, Marie Markert is an employee of Ferring Pharmaceuticals and Jeremy Carette and Henri Leleu have received consultancy fees. Ethics approval: Not applicable. The study only used previously published data that received ethical approval and consent to participate. Consent to participate: Not applicable. The study only used previously published data that received ethical approval and consent to participate. Consent for publication (from patients/participants): Not applicable. The study only used previously published data that received ethical approval and consent to participate. Data availability: Ferring Pharmaceuticals A/S will provide access to data upon reasonable request, via a secure portal, to researchers whose proposals meet the research criteria and other conditions, while ensuring compliance to patient privacy regulations. To gain access, data requestors must enter into a data access agreement with Ferring. Code availability: Transmission of the model may be provided upon request with appropriate authorization from Ferring. Author contributions: All authors contributed to the design and implementation of the research, to the analysis of the results, and to the writing and validation of the manuscript.*